The latest price target for Accelerate Diagnostics (NASDAQ:AXDX) was reported by Craig-Hallum on April 1, 2024. The analyst firm set a price target for $1.00 expecting AXDX to fall to within 12 months (a possible -16.49% downside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Accelerate Diagnostics (NASDAQ:AXDX) was provided by Craig-Hallum, and Accelerate Diagnostics maintained their hold rating.

There is no last upgrade for Accelerate Diagnostics

The last downgrade for Accelerate Diagnostics Inc happened on March 9, 2022 when Craig-Hallum changed their price target from N/A to $5 for Accelerate Diagnostics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Accelerate Diagnostics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Accelerate Diagnostics was filed on April 1, 2024 so you should expect the next rating to be made available sometime around April 1, 2025.

While ratings are subjective and will change, the latest Accelerate Diagnostics (AXDX) rating was a maintained with a price target of $2.00 to $1.00. The current price Accelerate Diagnostics (AXDX) is trading at is $1.20, which is out of the analyst’s predicted range.